{"groups":[{"description":"Participants received 0.08 or 0.1 mg of Pegilodecakin once daily (QD) administered subcutaneously (SC).\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG000","title":"Part A: Pegilodecakin 0.08/0.1 mg"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG001","title":"Part A: Pegilodecakin 0.2/0.25 mg"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG002","title":"Part A: Pegilodecakin 0.4/0.5 mg"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG003","title":"Part A: Pegilodecakin 0.8/1 mg"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG004","title":"Part A: Pegilodecakin 1.6/2 mg"},{"description":"Participants received 3.2 or 4 mg of Pegilodecakin QD administered SC. Study treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG005","title":"Part A: Pegilodecakin 3.2/4 mg"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG006","title":"Part B: Pegilodecakin 0.2/0.25 mg + Platinum/Taxane"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG007","title":"Part B: Pegilodecakin 0.4/0.5 mg + Platinum/Taxane"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC along with Platinum/Taxane combination on Day 1 of each 21-day cycle for a maximum of 5 or 6 cycles. Participants received:\n\nPaclitaxel 200 or 175 mg/m² intravenously (IV) over 3 hours, or docetaxel 75 or 65 mg/m² IV over 1 hour, followed by carboplatin (AUC 6/5/4; max 6 × 150 mg) IV over 30 minutes or cisplatin 75 mg/m² IV over 6-8 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG008","title":"Part B: Pegilodecakin 0.8/1 mg + Platinum/Taxane"},{"description":"Participants received 0.2 or 0.25 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-Fluorouracil (FU) 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG009","title":"Part C: Pegilodecakin 0.2/0.25 mg + FOLFOX"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG010","title":"Part C: Pegilodecakin 0.4/0.5 mg + FOLFOX"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC and FOLFOX treatment on Day 1 of each 14-day cycle for a maximum of 12 cycles. Participants received:\n\noxaliplatin 85 mg/m2 IV over 2 hours, and leucovorin 200 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, 5-FU 600 mg/m2/day IV over 22 hours, and leucovorin 200 mg/m2 over 2 hours on Day 2 followed by 5-FU 400 mg/m2 IV bolus over 2-4 minutes, and 5-FU 600 mg/m2/day IV over 22 hours.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG011","title":"Part C: Pegilodecakin 0.8/1 mg + FOLFOX"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC with Gemcitabine 1000 mg/m2 IV over 30 minutes plus nab-paclitaxel 125 mg/m2 IV over 30 to 40 minutes on Days 1, 8, and 15 of every 28-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG012","title":"Part D: Pegilodecakin 0.4/ 0.5 mg + Gemcitabine/Nab-Paclitaxel"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Capecitabine 1000 mg/m² orally twice daily (BID) on Days 1 through 14 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG013","title":"Part E: Pegilodecakin 0.8/1 mg + Capecitabine"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Paclitaxel 80 mg/m2 IV over 3 hours on Days 1, 8, and 15 of every 28-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG014","title":"Part F: Pegilodecakin 0.8/ 1 mg + Paclitaxel"},{"description":"Participants received a 0.8 or 1 mg of Pegilodecakin QD administered SC with Pazopanib 800 mg orally QD.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG015","title":"Part G: Pegilodecakin 0.8/1 mg + Pazopanib"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG016","title":"Part H: Pegilodecakin 0.8/1 mg + Pembrolizumab"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG017","title":"Part H: Pegilodecakin 1.6/2 mg + Pembrolizumab"},{"description":"Participants received 3.2 or 4 mg of Pegilodecakin QD administered SC with Pembrolizumab 2 mg/kg bolus IV infusion over 30 minutes on Day 1 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG018","title":"Part H: Pegilodecakin 3.2/4 mg + Pembrolizumab"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with Nivolumab 3 mg/kg IV infusion over 60 minutes on Day 1 of each 14-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG019","title":"Part I: Pegilodecakin 0.8/1 mg + Nivolumab"},{"description":"Participants received 1.6 or 2 mg of Pegilodecakin QD administered SC with Nivolumab 3 mg/kg IV infusion over 60 minutes on Day 1 of each 14-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG020","title":"Part I: Pegilodecakin 1.6/2 mg + Nivolumab"},{"description":"Participants received 0.4 or 0.5 mg of Pegilodecakin QD administered SC with gemcitabine 500 mg/m2 IV over 30 minutes followed by carboplatin targeting an Area Under the Curve of 2 mg/mL x min (AUC2) IV over 60 minutes on Days 1 and 8 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG021","title":"Part J: Pegilodecakin 0.4/0.5 mg + Gemcitabine/Carboplatin"},{"description":"Participants received 0.8 or 1 mg of Pegilodecakin QD administered SC with gemcitabine 500 mg/m2 IV over 30 minutes followed by carboplatin targeting an AUC2 IV over 60 minutes on Days 1 and 8 of each 21-day cycle.\n\nStudy treatment continued until disease progression, death, unacceptable toxicity, or end of trial.","id":"FG022","title":"Part J: Pegilodecakin 0.8/1 mg + Gemcitabine/Carboplatin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"2"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"8"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"}],"type":"Patient withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"1"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"1"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"2"},{"groupId":"FG018","numSubjects":"2"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"11"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"}],"type":"Sponsor's decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"1"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"1"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"1"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"2"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"0"},{"groupId":"FG017","numSubjects":"1"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"1"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"105"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"14"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"27"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"6"},{"groupId":"FG013","numSubjects":"6"},{"groupId":"FG014","numSubjects":"6"},{"groupId":"FG015","numSubjects":"4"},{"groupId":"FG016","numSubjects":"8"},{"groupId":"FG017","numSubjects":"29"},{"groupId":"FG018","numSubjects":"3"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"33"},{"groupId":"FG021","numSubjects":"5"},{"groupId":"FG022","numSubjects":"5"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"117"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"18"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"29"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"6"},{"groupId":"FG013","numSubjects":"6"},{"groupId":"FG014","numSubjects":"6"},{"groupId":"FG015","numSubjects":"6"},{"groupId":"FG016","numSubjects":"14"},{"groupId":"FG017","numSubjects":"34"},{"groupId":"FG018","numSubjects":"5"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"57"},{"groupId":"FG021","numSubjects":"5"},{"groupId":"FG022","numSubjects":"5"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"117"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"18"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"29"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"6"},{"groupId":"FG013","numSubjects":"6"},{"groupId":"FG014","numSubjects":"6"},{"groupId":"FG015","numSubjects":"6"},{"groupId":"FG016","numSubjects":"14"},{"groupId":"FG017","numSubjects":"34"},{"groupId":"FG018","numSubjects":"5"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"57"},{"groupId":"FG021","numSubjects":"5"},{"groupId":"FG022","numSubjects":"5"}],"type":"Participants Who Received at Least One Dose of the Study Intervention."},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"},{"groupId":"FG015","numSubjects":"0"},{"groupId":"FG016","numSubjects":"2"},{"groupId":"FG017","numSubjects":"0"},{"groupId":"FG018","numSubjects":"0"},{"groupId":"FG019","numSubjects":"0"},{"groupId":"FG020","numSubjects":"2"},{"groupId":"FG021","numSubjects":"0"},{"groupId":"FG022","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"116"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"3"},{"groupId":"FG008","numSubjects":"18"},{"groupId":"FG009","numSubjects":"4"},{"groupId":"FG010","numSubjects":"29"},{"groupId":"FG011","numSubjects":"6"},{"groupId":"FG012","numSubjects":"6"},{"groupId":"FG013","numSubjects":"6"},{"groupId":"FG014","numSubjects":"6"},{"groupId":"FG015","numSubjects":"6"},{"groupId":"FG016","numSubjects":"12"},{"groupId":"FG017","numSubjects":"34"},{"groupId":"FG018","numSubjects":"5"},{"groupId":"FG019","numSubjects":"1"},{"groupId":"FG020","numSubjects":"55"},{"groupId":"FG021","numSubjects":"5"},{"groupId":"FG022","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}